Si Li

The State Key Lab Of Translational Medicine And Innovative Drug Development
Nanjing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Extensive small cell lung cancer treated by integrated traditional Chinese and Western medicine: A case report.

Extensive small cell lung cancer treated by integrated traditional Chinese and Western medicine: A case report.

Journal: Medicine

Published: January 20, 2025

Molecular and immunological characteristics of postoperative relapse in lymph node-positive esophageal squamous cell cancer.

Molecular and immunological characteristics of postoperative relapse in lymph node-positive esophageal squamous cell cancer.

Journal: Cancer medicine

Published: November 14, 2023

Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment.

Genomic profiling of non-small cell lung cancer with the rare pulmonary lymphangitic carcinomatosis and clinical outcome of the exploratory anlotinib treatment.

Journal: Frontiers in oncology

Published: July 12, 2022

PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.

PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non-small cell lung cancer.

Journal: Cell proliferation

Published: April 14, 2022

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR-ROS1 Fusion.

Case Report: Adjuvant Crizotinib Therapy Exerted Favorable Survival Benefit in a Resectable Stage IIIA NSCLC Patient With Novel LDLR-ROS1 Fusion.

Journal: Frontiers in oncology

Published: December 16, 2021

Reversing resistance to immune checkpoint inhibitor by adding recombinant human adenovirus type 5 in a patient with small cell lung cancer with promoted immune infiltration: a case report.

Reversing resistance to immune checkpoint inhibitor by adding recombinant human adenovirus type 5 in a patient with small cell lung cancer with promoted immune infiltration: a case report.

Journal: Journal of cancer research and clinical oncology

Published: November 04, 2021

Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.

Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.

Journal: Translational lung cancer research

Published: August 27, 2021

Genomic landscape and tumor mutation burden analysis of Chinese patients with sarcomatoid carcinoma of the head and neck.

Genomic landscape and tumor mutation burden analysis of Chinese patients with sarcomatoid carcinoma of the head and neck.

Journal: Oral oncology

Published: June 21, 2021

Chr1 95026203-ALK, a novel intergenic fusion identified in a patient with lung adenocarcinoma with nodular ground-glass opacity.

Chr1 95026203-ALK, a novel intergenic fusion identified in a patient with lung adenocarcinoma with nodular ground-glass opacity.

Journal: Journal of thoracic disease

Published: April 19, 2021

Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer.

Helicobacter pylori infection as a potential favorable factor for immune checkpoint inhibitor therapy for gastric cancer.

Journal: Investigational new drugs

Published: March 29, 2021

A novel DPP10 (intergenic)-NTRK3 fusion in a patient with facial malignant melanoma and potentially benefit from NTRK inhibitors.

A novel DPP10 (intergenic)-NTRK3 fusion in a patient with facial malignant melanoma and potentially benefit from NTRK inhibitors.

Journal: Oral oncology

Published: March 22, 2021

Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation.

Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation.

Journal: Investigational new drugs

Published: March 16, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026